D-Weill Cornell Medical College in Qatar-type 2 diabetes mellitus

This entry refers to a clinical research program or specific trial (NCT02690181) conducted by Weill Cornell Medical College in Qatar focused on the management of type 2 diabetes mellitus. The study is a randomized, open-label trial comparing the efficacy and safety of two long-acting basal insulin analogues: **insulin degludec** and **insulin glargine U100**. The research specifically targets patients who observe fasting during the month of Ramadan, a period that necessitates significant adjustments in meal timing and medication schedules. The primary objective is to evaluate glycemic control, as measured by continuous glucose monitoring and HbA1c levels, and to monitor the incidence of hypoglycemic episodes to determine the most effective and safest insulin regimen for this population during religious fasting.

Other names

Insulin Degludec vs Insulin Glargine U100 in Ramadan Study